Pharma deals indicate promise of RNAi therapeutics

07/24/2008 | InPharm.com

Novartis has extended its collaboration with Alnylam Therapeutics and Roche has purchased gene-silencing specialist Mirus Bio Corp., an indication that the drug industry recognizes the research and commercial possibilities in RNAi-based therapeutics for a range of diseases. A Novartis official said RNAi "holds great potential," adding, "In particular, this new area of biology has potential to treat diseases that have not been able to be addressed by traditional approaches."

View Full Article in:

InPharm.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR